Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Double-Blind, Placebo-Controlled Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease

NCT02110901 is registered in ClinicalTrials.gov with Proteon Therapeutics as lead sponsor.

NCT NCT02110901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02110901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Double-Blind, Placebo-Controlled Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Lead sponsor
Proteon Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2014
Completion date
December 31, 2018
Enrollment
349 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease